Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Deutsche Medizinische Wochenschrift (1946)
|
August 3, 2021
[Long-lasting souvenir from Cameroon - Persistent, massive hypereosinophilia in amicrofilaremic infection with Loa loa]
Lisa Meffert, Friederike Schmitz, Jana Ziob
International Journal of Molecular Sciences
|
May 28, 2020
The Role of Immune Checkpoints after Cellular Therapy
Friederike Schmitz, Dominik Wolf, Tobias A W Holderried
Transplantation and Cellular Therapy
|
September 19, 2024
Antibiotic Prophylaxis During Allogeneic Stem Cell transplantation-A Comprehensive Single Center Retrospective Analysis
Charlotte K F Neuerburg, Friederike Schmitz, Marie-Therese Schmitz, et al.
Frontiers in Digital Health
|
November 5, 2024
Unleashing the potential of eHealth in outpatient cancer care for patients undergoing immunotherapy-a quantitative study considering patients' needs and current healthcare challenges
Tobias A W Holderried, Isabel Stasik, Marie-Therese Schmitz, et al.
Ejhaem
|
September 2, 2025
Early Free Light-Chain Suppression as a Prognostic Marker in Relapsed and Refractory Myeloma Patients Treated With BCMA-Directed CAR-T Cells
Tim Richardson, Hishan Tharmaseelan, Guido Kobbe, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology
|
April 2, 2016
Loss of Biglycan Enhances Thrombin Generation in Apolipoprotein E-Deficient Mice: Implications for Inflammation and Atherosclerosis
Maria Grandoch, Christina Kohlmorgen, Ariane Melchior-Becker, et al.
Hemasphere
|
January 17, 2025
Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study
Maximilian Merz, Anca-Maria Albici, Bastian von Tresckow, et al.
Blood Cancer Journal
|
December 5, 2024
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy
Maximilian Merz, Danai Dima, Hamza Hashmi, et al.
Blood Cancer Discovery
|
June 12, 2026
Outcomes of CAR-T Cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma
Maximilian Merz, Tomas Jelinek, Thomas Pabst, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Deutsche Medizinische Wochenschrift (1946)
|
August 3, 2021
[Long-lasting souvenir from Cameroon - Persistent, massive hypereosinophilia in amicrofilaremic infection with Loa loa]
Lisa Meffert, Friederike Schmitz, Jana Ziob
International Journal of Molecular Sciences
|
May 28, 2020
The Role of Immune Checkpoints after Cellular Therapy
Friederike Schmitz, Dominik Wolf, Tobias A W Holderried
Transplantation and Cellular Therapy
|
September 19, 2024
Antibiotic Prophylaxis During Allogeneic Stem Cell transplantation-A Comprehensive Single Center Retrospective Analysis
Charlotte K F Neuerburg, Friederike Schmitz, Marie-Therese Schmitz, et al.
Frontiers in Digital Health
|
November 5, 2024
Unleashing the potential of eHealth in outpatient cancer care for patients undergoing immunotherapy-a quantitative study considering patients' needs and current healthcare challenges
Tobias A W Holderried, Isabel Stasik, Marie-Therese Schmitz, et al.
Ejhaem
|
September 2, 2025
Early Free Light-Chain Suppression as a Prognostic Marker in Relapsed and Refractory Myeloma Patients Treated With BCMA-Directed CAR-T Cells
Tim Richardson, Hishan Tharmaseelan, Guido Kobbe, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology
|
April 2, 2016
Loss of Biglycan Enhances Thrombin Generation in Apolipoprotein E-Deficient Mice: Implications for Inflammation and Atherosclerosis
Maria Grandoch, Christina Kohlmorgen, Ariane Melchior-Becker, et al.
Hemasphere
|
January 17, 2025
Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study
Maximilian Merz, Anca-Maria Albici, Bastian von Tresckow, et al.
Blood Cancer Journal
|
December 5, 2024
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy
Maximilian Merz, Danai Dima, Hamza Hashmi, et al.
Blood Cancer Discovery
|
June 12, 2026
Outcomes of CAR-T Cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma
Maximilian Merz, Tomas Jelinek, Thomas Pabst, et al.
Page
of 1